Disease severity and quality of life in patients with psoriasis: Special focus on hepatic panel
Keywords:
Psoriasis, PASI score, DLQI, depressive, psoriasis, Facial Lesions, questionnaire., Hepatic profileAbstract
Objective To assess the disease severity and QoL in ambulatory psoriasis patients in a tertiary care set-up, with a special focus on their hepatic profile. Methods The study included adult patients clinically diagnosed with psoriasis. Sociodemographic data, disease duration, psoriasis severity, complete hepatic functions were noted. Psoriasis severity and QoL were assessed using Psoriasis Area and Severity Index (PASI) and Dermatology Quality of Life Index (DLQI). Data was statistically analyzed. Results Mean duration of disease was noted to be 4.85 years among the study population. Mean PASI score observed was 15.04±11.41, while the mean DLQI score was 4.97±3.13. The psoriasis flare was seen in significantly increasing mark for the initial 20 years, followed by later steep decline. QoL however did not show any abrupt changes over the years. Both psoriasis severity and QoL were positively associated with SGOT, SGPT and albumin levels. PASI and DLQI score were both positively correlated with duration of disease (r=0.69, p<0.05). Psoriasis severity and QoL were also found to have significant positive association, suggesting poorer QoLwith increased disease severity (r=0.268, p=0.001). Conclusion Disease severity has been the sole significant predictor of impaired QoL in psoriasis. The study however did not observe significant hepatic abnormalities in the cohort of subjects. Periodic monitoring and treatment of associated conditions can help to achieve better patient outcomes in these chronic treatment scenarios.References
WHO- Global Report on Psoriasis. Accessed at https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf?sequence=1&isAllowed=y . Accessed on May 30, 2022.
Finet A, Viguier M, Chazouillères O, Amatore F, Paul C, Richard MA, Chosidow O, Bachelez H, Sbidian E; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie. Liver test abnormalities in patients admitted for severe psoriasis: prevalence and associated risk factors. J EurAcad Dermatol Venereol. 2016;30(10):1742-8.
Miele L, Vallone S, Cefalo C et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778-86.
Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol. 2012;53:190-7.
Roberts KK, Cochet AE, Lamb PB, Brown PJ, Battafarano DF, Brunt EM, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41:293-300.
Megari K. Quality of Life in Chronic Disease Patients. Health Psychol Res. 2013;1(3):e27.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6.
Griffiths, C., Jo, S.-J., Naldi, L., Romiti, R., Guevara-Sangines, E., Howe, T., Pietri, G., Gilloteau, I., Richardson, C., Tian, H. and Augustin, M. (2018), A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179:173-81.
Blome C, Augustin M, Behechtnejad J, Rustenbach SJ. Dimensions of patient needs in dermatology: subscales of the patient benefit index. Arch Dermatol Res. 2011;303(1):11-7.
Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859-66.
Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
Belinchón-Romero I, Bellot P, Romero-Pérez D, Herraiz-Romero I, Marco F, Frances R, et al. Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. Sci Rep. 2021;11(1):8593.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-12.
Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. Biomed Res Int. 2018;2018:3140983.
Mancini S., Amorotti E., Vecchio S., de Leon M. P., Roncucci L. Infliximab-related hepatitis: Discussion of a case and review of the literature. Int Emerg Med. 2010;5(3):193-200.
Prussick R, Prussick L, Nussbaum D. Nonalcoholic Fatty liver disease and psoriasis: what a dermatologist needs to know. J Clin Aesthet Dermatol. 2015;8(3):43-5.
Campanati A, Ganzetti G, Di Sario A, Damiani A, Sandroni L, Rosa L, Benedetti A, Offidani A. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol. 2013;48:839-46.
Mahajan VK, Chauhan NS, Rana BS, Mehta KS, Hooda S, Chauhan PS, Kukreja A. The Association Between Chronic Plaque Psoriasis and Nonalcoholic Fatty Liver Disease in Indian Patients: Results of a Pilot Study. J Clin Exp Hepatol. 2022;12(3):785-92.
Paul S, Das A, Ghosh C. Efficacy and safety of isotretinoin in comparison to methotrexate in the patients suffering from moderate-to-severe plaque psoriasis: A prospective cohort study. Asian J Med Sci. 2022;13(4):66-72.
Das S, Das NK, Basu SS. Quality of life of Psoriasis patients of a tertiary care centre of Eastern India. Medica innovatica. 2020;9(2):103-8.
Nagrani P, Roy S, Jindal R. Quality of life in psoriasis: a clinical study. Int J Res Dermatol. 2019;5(2):319-24.
Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A. Psoriasis affects patient's quality of life more seriously in female than in male in Japan. Tokai J Exp Clin Med. 2012;37(3):84-8.
